Massive Overreaction!, page-6

First 6 Last

Share
Profile

Follow
CptAwesome

831 Posts.

26

09/12/16

22:59

Post #: 21241226
Share

Originally posted by fifty cents ↑

"On a full year basis, worldwide dose sales growth is anticipated to be in the order of 5-11% compared to growth of 16.4% achieved in FY16."

Given the number of clinical trials due to report in first half CY17 and the probability of the treatment going from salvage to standard of care or first line, I think this has been a massive overreaction today. I believe the strong bounce will continue next week as people reconsider the long term value.

Judging by the share price today it would be easy to think its a company with a large amount of debt announcing a huge loss for the year however nothing could be further from the truth!

The company has no debt.

Dose sales are continuing to grow

Profits are growing!

Growing dividends!

Profitable!

Massive and growing amount of Cash in the bank

Massive margins!

In addition to the Sirspheres there are at least four other technologies in the pipeline of which if any of these makes it to market it has the potential to add serious revenue.

Even without the upcoming trials or the technology in the pipeline it is a strong growing company with a fantastic balance sheet and cash-flow with what appears to be a minor blip in dose sales growth this FY however growing nonetheless!

Look at the balance sheet, the dose sales, the upcoming trials, the technology pipeline and the fact that in bad times dose sales are still expected to be 5-11%!

Perhaps I'm overly optimistic. Anyway just some facts and my opinion. What people choose to buy and sell their shares at each day is not my business

Expand

I sold out a long time ago. This is not an over reaction. If you factor in the 'new' growth target then its probably a little expensive again.

SRX Price at posting: $16.00 Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BUX

Buxton projects new graphite province discovery at WA Narryer play

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

There are more pages in this discussion • 20 more messages in this thread...

First 6 Last

Add SRX (ASX) to my watchlist

Massive Overreaction!, page-6

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News